To the Editor: A uterine carcinosarcoma (malignant mixed Müllerian tumor [MMMT]) is a rare, aggressive, malignant tumor which demonstrates both malignant epithelial (carcinoma) and mesenchymal (sarcoma) components.[1] MMMTs account for 2–5% of all uterine malignancies. Metastatic progression is uncommon and occurs through hematologic, lymphatic, and intraperitoneal spread. Risk factors for MMMTs include radiation, excessive estrogen exposure, obesity, and nulliparity. The 2-year survival rate for patients with MMMTs is 53% for Stage I disease and decreases to 8.5% for Stages II and III.[2]

Uterine inversion involves a trapped uterine fundus, which in turn causes the endometrium to protrude through the cervix to the vagina. Uterine inversion can be divided into the following three types: (1) incomplete uterine inversion, in which the uterine fundus descends inferiorly but does not pass through the external cervical os; (2) complete uterine inversion, in which the fundus and corpus extend through the external os; and (3) total uterine inversion, in which the vagina is also inverted.[3] In the process of diagnosis and treatment, uterine inversion patients usually have combined symptoms of severe pain, bleeding, infections and shock labor performance, the precondition of which include relief pain, controlled hemorrhage, infection and shock. The differential diagnosis included the submucous myoma of uterus and uterine prolapse, vaginal wall cyst, or vaginal wall prolapsed. Lupovitch A, et al.[4] reported a rare case of uterus inversion happened in endometrial sarcoma of the uterus. Nonpuerperal uterine inversion with endometrial carcinosarcoma is an unusual condition but can occur in the postmenopausal age group. Clinical diagnosis of the disease is difficult and can sometimes be fatal. This study introduced a case of uterus inversion combined with endometrial carcinosarcoma.

A 74-year-old Chinese woman complained of irregular vaginal bleeding for 6 months and a vaginal mass for 30 days. Due to urination and gravity, the vaginal mass descended to the vulva. The mass was 10 cm × 8 cm × 7 cm in size and accompanied by substantial vaginal bleeding. A physician in another hospital performed uterine artery embolization and biopsied the mass, which was shown to be a uterine carcinosarcoma. The vaginal hemorrhage decreased significantly postoperatively. The medical history was unremarkable and she had no prior surgeries. There was no family history of uterine myomas or malignancies.

The patient came to our hospital for further evaluation. The vaginal examination revealed a large polypoid mass that was thought to be a prolapsed uterus [Figure 1]. Pelvic ultrasonography revealed no uterine echo in the pelvic cavity. A magnetic resonance imaging (MRI) of the pelvis showed that the uterus and carcinosarcoma had prolapsed through the vagina. The tumor markers were normal with the exception of CA-125 (607.20 U/ml). The primary diagnosis was endometrial carcinosarcoma combined with inversion of the uterus. For treatment, a laparotomy was planned. Because of the hypercoagulable state (D-dimer >17.2 mg/L), the patient was given a low-molecular-weight heparin sodium injection twice daily until the D-dimer level approached normal. The inverted uterus and vulva were cleaned daily. To avoid intraoperative bleeding, artery embolization was repeated on the day before surgery. Exploration during laparotomy showed that the uterine...
Patterns of care, predictors and outcomes of carcinosarcoma were not palpable, and because of comorbidities and the physical condition of the patient, a lymphadenectomy was not performed. The benefit of the role of lymphadenectomy, and omentectomy.

Inversion of the uterus is a rare condition which is an obstetric emergency and a diagnostic challenge for gynecologists. Nonpuerperal uterine inversion is often associated with leiomyomas, sometimes associated with uterine sarcomas, but very rarely associated with endometrial carcinosarcoma. A typical presentation of carcinosarcoma combined with uterus inversion includes pyometra with vaginal bleeding, bloody or watery discharge, abdominal pain, or a polypoid mass in a postmenopausal woman. In such cases, it is easy to misdiagnose a uterine carcinosarcoma as a cervical tumor.

Uterine inversion is suspected when a tumor is present in the vagina, but the uterine fundus is not palpable by pelvic examination. It is noteworthy that an MRI or computed tomography (CT) scan is a useful tool in the diagnosis of nonpuerperal inversion of the uterus. In the present case, the inverted uterus and endometrial carcinosarcoma were observed in the vulva. The vagina was inverted as well, which is rare and consistent with a total inverted uterus. Ultrasonography demonstrated no uterine corpus in the pelvis. An MRI examination showed a total inverted uterus and a malignant mass involving the endometrium. The etiologic factors leading to an inverted uterus and carcinosarcoma include (a) sudden extrusion of a tumor from the uterus, (b) thin uterine wall, (c) dilatation of the uterine cervix, and (d) tumor size. The primary treatment or uterine carcinosarcoma with uterine inversion is surgical, including total hysterectomy, bilateral salpingo-oophorectomy, bilateral pelvic lymphadenectomy, and omentectomy.[5,6] The final histologic evaluation confirmed the diagnosis of Stage IIIb carcinosarcoma. The behavior of carcinosarcomas is characterized mainly based on the carcinomatous component, thus carcinosarcomas metastasize to the lymph nodes. The benefit of the role of lymphadenectomy was apparent. In our case, the pelvic and para-aortic lymph nodes were not palpable, and because of comorbidities and the physical condition of the patient, a lymphadenectomy was not performed.

Radiotherapy is suggested in the literature as another option for the treatment of uterine malignancies. In general, it is known that the 5-year survival of patients with uterine carcinosarcomas receiving radiotherapy versus no irradiation was 41.5% and 33.2%, respectively.[7] A retrospective study assessed the efficacy and toxicity of a novel combination chemotherapy using carboplatin, ifosfamide, and mesna compared with other regimens for patients in adjuvant and palliative settings. Indeed, combined adjuvant radiotherapy and chemotherapy may increase the 5-year survival rate.[8]

Declarations of patient consent
The authors certify that they have obtained all the appropriate patient consent forms. The guardians have given their consent for patients images and other clinical information to be reported in the journal. The guardians understand that patient's names and initials will not be published and due efforts will be made to conceal their identity, but anonymity cannot be guaranteed.

Financial support and sponsorship
Nil.

Conflicts of interest
There are no conflicts of interest.

References
1. Arend R, Doneza JA, Wright JD. Uterine carcinosarcoma. Curr Opin Oncol 2011;23:531-6. doi: 10.1097/COC.0b013e328349a45b.
2. Williamson JM, Stevens M, Mahon D. Metachronous small bowel metastasis from a mixed müllerian mesodermal tumour. Ann R Coll Surg Engl 2016;98:e26-8. doi: 10.1308/rcsann.2016.0032.
3. de Vries M, Perquin DA. Non-puerperal uterine inversion due to submucous myoma in a young woman: A case report. J Med Case Rep 2010;4:21. doi: 10.1186/1752-1947-4-21.
4. Lupovitch A, England ER, Chen R. Non-puerperal uterine inversion in association with uterine sarcoma: Case report in a 26-year-old and review of the literature. Gynecol Oncol 2005;97:938-41. doi: 10.1016/j.ygyno.2005.02.024.
5. Oguri H, Maeda N, Yamamoto Y, Wakatsuki A, Fukaya T. Non-puerperal uterine inversion associated with endometrial carcinosarcoma – A case report. Gynecol Oncol 2005;97:973-5. doi: 10.1016/j.ygyno.2005.02.023.
6. Delligoer TH, Wakabayashi MT, Han ES. Comprehensive staging of uterine carcinosarcoma using a multiquadrant robotic platform. J Minim Invasive Gynecol 2017;24:531-2. doi: 10.1016/j.jmig.2016.10.010.
7. Cha J, Kim YS, Park W, Kim HJ, Kim JY, Kim JH, et al. Clinical significance of radiotherapy in patients with primary uterine carcinosarcoma: A multicenter retrospective study (KROG 13-08). J Gynecol Oncol 2016;27:e58. doi: 10.3802/jgo.2016.27.e58.
8. Rauh-Hain JA, Starbuck KD, Meyer LA, Clemmer J, Schorge JO, Lu KH, et al. Patterns of care, predictors and outcomes of chemotherapy for uterine carcinosarcoma: A National cancer database analysis. Gynecol Oncol 2015;139:84-9. doi: 10.1016/j.ygyno.2015.08.014.